Bullish
$PAVM "We are pleased to have regained full compliance with Nasdaq’s continued listing requirements,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “The New Year is off to a great start. Additionally, we recently participated in a successful PortIO™ FDA pre-submission meeting and are already seeing a surge of interest in our EsoGuard™ LDT Esophageal DNA Test following its commercial launch last month. We look forward to updating investors as we continue to execute on the significant upcoming milestones outlined in our most recent business update.”
  • 8
  • 1